Entecavir

證據等級: L5

預測適應症: 10 個

I reviewed the evidence pack closely. One thing worth flagging before the report: predicted_indications[0] (chronic hepatitis C) is the disease the template's field-extraction rules point to for the title/Quick Overview — but the evidence pack's own repurposing_rationale explicitly labels this a TxGNN false positive (no shared drug target, all cited trials/literature are actually about HBV or HBV/HCV coinfection management, not HCV efficacy). I've written the report to follow the template structure exactly while reporting that finding honestly rather than dressing it up as a promising lead — that's what "Hold" and L5 mean here.

Entecavir: From Chronic Hepatitis B to Chronic Hepatitis C Virus Infection

One-Sentence Summary

Entecavir is a nucleoside analogue approved for chronic hepatitis B (HBV), where it inhibits the HBV reverse transcriptase. The TxGNN model's top-ranked signal predicts possible activity against Chronic Hepatitis C Virus Infection, but on review, none of the 40 clinical trials or 20 publications retrieved for this pairing actually test entecavir against HCV — they concern HBV treatment or HBV/HCV coinfection management, and the evidence level is L5 (model prediction only).

Quick Overview

Item	Content
Original Indication	Chronic Hepatitis B (established indication, referenced in supporting evidence — no formal German market license record was available; see Germany Market Information)
Predicted New Indication	Chronic Hepatitis C Virus Infection
TxGNN Prediction Score	99.98%
Evidence Level	L5
Germany Market Status	Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism-of-action data for entecavir was not available in the evidence pack. Based on the information present, entecavir is a deoxyguanosine nucleoside analogue whose established pharmacological target is the hepatitis B virus (HBV) reverse transcriptase — it blocks priming, pgRNA reverse transcription, and second-strand DNA synthesis, and this is the basis of its approved use in chronic hepatitis B.

Hepatitis C virus (HCV), by contrast, is a Flaviviridae RNA virus that replicates via an RNA-dependent RNA polymerase (NS5B), a structurally and mechanistically distinct enzyme with no known cross-reactivity to entecavir's HBV-targeted reverse-transcriptase inhibition. The evidence pack's own mechanistic assessment concludes there is no pharmacological basis for cross-activity.

Consistent with this, the clinical trials and literature returned for the "entecavir + HCV" query do not actually test entecavir's efficacy against HCV. They are HBV treatment trials, or studies of HBV/HCV coinfection management (e.g., HBV reactivation risk during HCV direct-acting antiviral therapy) that surfaced only because "hepatitis B and C" appear together in the same abstracts. This pattern is characteristic of a TxGNN false positive driven by textual/semantic similarity between "viral hepatitis" disease nodes, rather than a genuine drug-target relationship. Notably, the model separately and correctly assigns entecavir to its actual known indication, hepatitis B virus infection (score 99.85%, evidence level L1, driven by real Phase 3 registration trials such as NCT00036608, NCT00410202, and NCT01079806) — which validates that the model can identify true relationships, but underscores that the HCV signal is not one of them.

Clinical Trial Evidence

Of the 40 clinical trials returned for the "entecavir + chronic HCV" query, only a subset has been reviewed for relevance; all reviewed trials were graded low-relevance (C) because they involve entecavir treating HBV, not HCV. No trial in the retrieved set tests entecavir's efficacy against HCV itself.

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01179594	Phase 4	Withdrawn	0	Peginterferon alfa-2a ± entecavir in HBeAg-negative chronic hepatitis B — not an HCV trial; withdrawn with zero enrollment.
NCT01022801	Phase 2	Completed	120	Entecavir vs. lamivudine dose-response in Japanese chronic hepatitis B patients — HBV only, no HCV arm.
NCT02956850	Phase 1	Completed	160	Placebo-controlled safety/PK study of RO7020531 in chronic hepatitis B — entecavir/HCV relevance could not be confirmed from available detail.

The remaining ~37 trials in the retrieved set are unclassified (pending review) but, based on their titles and summaries, follow the same pattern — nucleos(t)ide analogue therapy for chronic hepatitis B, HBV/HCV coinfection reactivation monitoring, or unrelated hepatitis B pharmacology studies. None report an HCV efficacy endpoint for entecavir.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
16937041	2006	Review (Tier 3)	Wiener medizinische Wochenschrift	Reviews chronic hepatitis B and C treatment as parallel but separate disease tracks; does not test entecavir against HCV.
24773464	2014	Review (Tier 3)	Expert Opinion on Pharmacotherapy	Advances in managing HBV/HCV coinfection; entecavir discussed only as the HBV-directed component of coinfection care.
22959099	2013	Review (Tier 3)	Clinics and Research in Hepatology and Gastroenterology	Discusses the therapeutic challenge of HBV/HCV dual infection; no data on entecavir activity against HCV itself.

The remaining literature hits (e.g., PMID 28487602, 32173307, 24868325) follow the same pattern — HBV/HCV are discussed together as co-occurring liver diseases or coinfection management topics, not as evidence of entecavir efficacy against HCV.

Germany Market Information

Entecavir is currently not marketed in the source regulatory dataset (0 authorizations on record). No product license, dosage form, or approved-indication text was available to report.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The chronic hepatitis C signal is not supported by mechanism (entecavir targets HBV reverse transcriptase; HCV replicates via an unrelated RNA polymerase) or by the retrieved evidence — every clinical trial and publication reviewed addresses HBV treatment or HBV/HCV coinfection management, not entecavir's efficacy against HCV. This is best interpreted as a TxGNN false positive arising from semantic proximity between hepatitis-virus disease nodes, at evidence level L5 (model prediction only, no confirmatory studies).

To proceed, the following is needed:

In vitro evidence (e.g., HCV replicon assay) demonstrating any direct antiviral activity of entecavir against HCV, which is currently absent
A review of the TxGNN knowledge-graph edges underlying this prediction to determine whether the hepatitis B/C node relationship reflects a data or embedding artifact
Full DrugBank mechanism-of-action and TFDA/BfArM package insert data for entecavir, both currently unavailable (data gaps DG001, DG002 in this evidence pack), to support any future S1 safety pre-screen

Additional note on other TxGNN-ranked candidates for entecavir: across the 10 disease nodes evaluated in this evidence pack, only two show any evidentiary substance — the model's independent, high-confidence recovery of entecavir's true indication, chronic hepatitis B (L1, Proceed with Guardrails — useful as a model-validity check, not a new opportunity), and a preclinical signal in animal hepadnaviral hepatitis (L3, woodchuck model, PMID 11679911) reflecting entecavir's established antiviral mechanism in a related hepadnavirus. All other candidates (HIV, feline/simian immunodeficiency virus, a rare neurodevelopmental disorder, HEV, HAV) were assessed as Hold with L5 evidence and no plausible mechanistic link.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.